Novartis Launching Lamisil AT With $20 Mil. TV/Print Ad Campaign
This article was originally published in The Tan Sheet
Executive Summary
Novartis plans to spend $20 mil. on TV and print advertising in 1999 to launch Lamisil AT, the firm's new OTC athlete's foot medication. An Rx-to-OTC switch of the 1% terbinafine cream was approved by FDA March 9 ("The Tan Sheet" March 15, p. 11).
You may also be interested in...
Lamisil AT Spray Pump, Solution Dropper Line Extensions Launching June 1
Novartis Lamisil AT Spray Pump and Solution Dropper, both terbinafine hydrochloride solution 1%, are launching June 1, "just in time for the peak summer athlete's foot season," the firm said. FDA approved the Rx-to-OTC switch March 17. Novartis filed the NDA (21-124) for the topical solution with the agency May 14, 1999.
Lamisil AT Spray Pump, Solution Dropper Line Extensions Launching June 1
Novartis Lamisil AT Spray Pump and Solution Dropper, both terbinafine hydrochloride solution 1%, are launching June 1, "just in time for the peak summer athlete's foot season," the firm said. FDA approved the Rx-to-OTC switch March 17. Novartis filed the NDA (21-124) for the topical solution with the agency May 14, 1999.
Lamisil AT Spray Pump, Solution Dropper Line Extensions Launching June 1
Novartis Lamisil AT Spray Pump and Solution Dropper, both terbinafine hydrochloride solution 1%, are launching June 1, "just in time for the peak summer athlete's foot season," the firm said. FDA approved the Rx-to-OTC switch March 17. Novartis filed the NDA (21-124) for the topical solution with the agency May 14, 1999.